THE EFFICACY AND SAFETY OF ALIROCUMAB IN PEDIATRIC PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: ODYSSEY KIDS
Volume: 75, Issue: 11, Pages: 1860 - 1860
Published: Mar 1, 2020
Abstract
A Phase 2 dose-finding study ([NCT02890992][1]) evaluated the efficacy, safety, and dose selection of the PCSK9 inhibitor alirocumab in pediatric patients with heterozygous familial hypercholesterolemia (HeFH).
Patients (N=42) aged 8–17 years, with body weight ≥25 kg and with HeFH and LDL-C...
Paper Details
Title
THE EFFICACY AND SAFETY OF ALIROCUMAB IN PEDIATRIC PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: ODYSSEY KIDS
Published Date
Mar 1, 2020
Volume
75
Issue
11
Pages
1860 - 1860
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History